Alzheimer's Drug Fight: NHS Watchdog Reconsiders

In a significant development for Alzheimer's treatment, the NHS spending watchdog has been directed to re-evaluate evidence concerning donanemab and lecanemab. These advanced antibody treatments, licensed in the UK in 2024, target amyloid buildup in the brain, aiming to slow cognitive decline by four to six months. However, their availability on the NHS was initially denied by the National Institute for Health and Care Excellence (NICE) due to perceived modest benefits and high costs, estimated to be five to six times the usual threshold.

Manufacturers Eli Lilly and Eisai successfully appealed NICE's final draft guidance published in June of last year. Key areas for reconsideration include the impact of the disease on Alzheimer's carers and the projected costs of administering the treatments via infusion. Pharmaceutical firms argued that crucial cost data was provided too late for adequate review. NICE has stated it will offer stakeholders another opportunity to submit further information to address uncertainties highlighted by the appeal panel, underscoring its commitment to a thorough assessment.

This reconsideration offers a "welcome glimmer of hope" for the Alzheimer's community, as highlighted by Eisai. While these drugs represent a breakthrough by addressing the disease's cause rather than just symptoms, patient advocacy groups emphasize the urgent need for treatments that help individuals maintain independence for longer. The UK is noted as falling behind other nations in accessing such therapies, with numerous other Alzheimer's drugs in late-stage trials, suggesting a rapidly evolving treatment landscape.